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ABSTRACT
Background: Venous thromboembolism (VTE), including deep vein thrombosis (DVT) and
pulmonary embolism (PE), is a rare but most likely fatal perioperative complication
associated with increased patient morbidity and mortality. COVID-19-positive patients with
VTE who present for surgery are predominantly asymptomatic and do not meet the
conventional definition and traditional diagnostic criteria. This presents a challenge in
identifying VTE in this patient population without proper surveillance and monitoring.
Objectives: The purpose of this study is to improve anesthesia providers’ knowledge of the
value of POCUS modality in preventing perioperative VTE in patients with COVID-19
undergoing noncardiac surgical procedures and improve recognition of associated risk factors
that predispose patients to the development of VTE. Investigators used CINAHL, MEDLINE,
and EMBASE databases to answer the PICO (i.e., population, intervention, comparison,
outcome) question: “In the adult patients with COVID-19 (P), does the use of the POCUS
modality as an adjunct to preoperative screening for DVT (I), compared to its non-use (C),
improve the early identification of perioperative VTE ( O)? The literature review provides the
educational framework to improve provider knowledge. The overall objective of the project
is to increase the quality of healthcare delivery to improve healthcare outcomes for patients
with COVID-19 undergoing noncardiac surgery.
Methodology: The primary methodology of the proposed project is to administer an online
educational intervention to providers which focuses on the benefits of perioperative POCUS
utilization in the early identification of VTEs. Pre- and post-assessment surveys will be used
to measure the improvement of provider knowledge before and after the intervention.
Results: Overall, there was an improvement in provider knowledge following the education
intervention. Additionally, the likelihood of utilizing the perioperative POCUS modality
increased among anesthesia providers.
Conclusion: The perioperative incorporation of the POCUS modality has been shown to
accurately assess the presence of DVT. The educational intervention provided effectively
improved anesthesia provider knowledge on the value of POCUS modality in preventing
perioperative VTE in patients with COVID-19 undergoing noncardiac surgical procedures
and improving recognition of associated risk factors that predispose patients to the
development of these events. Increasing awareness of the high incidence of thromboembolic
events in patients with COVID-19 and the role of POCUS in their early detection can reduce
mortality and improve postoperative outcomes.
Keywords: venous thromboembolism, deep vein thrombosis, pulmonary embolism, COVID19, coagulopathy, POCUS, point-of-care ultrasound, perioperative management
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Introduction
Description of the Problem
A novel Severe Acute Respiratory Syndrome Coronavirus type-2 (SARS-CoV-2), the
culprit of the COVID-19 pandemic, has been an ongoing public health threat, accounting for
millions of deaths worldwide. A cluster of unexplained pneumonia cases was first reported
from Wuhan, China, on December 31, 2019. The World Health Organization (WHO)
declared COVID-19 a public health emergency of international concern of January 30, 2020,
and by March 11, the spread of the infection had reached an alarming milestone of a global
pandemic.2 The United States reported its first confirmed case of SARS-CoV-2 infection on
January 20, 2020.1 It is currently one of the leading causes of mortality in the United States,
accounting for over 34 million cases and over 600,000 deaths as of this writing.1 Although
the overall incidence of COVID-19 has decreased since the rollout of the vaccine, the new
variants of SARS-CoV-2 continue to emerge and circulate across the globe, threatening to
overturn the progress made so far in halting the spread of the pandemic.1,2
Amid an ongoing pandemic, anesthesia providers routinely encounter and manage
patients with COVID-19 infection presenting for surgery. Perioperative management of
COVID-19-positive patients presents a myriad of unique challenges for anesthesia
professionals, as the surgery in this population is considered high-risk and is associated with
a greater incidence of viral transmission, cross-contamination of the perioperative
environment as well as the hazard of self-exposure during aerosol-generating procedures.3
Additionally, patients with COVID-19 undergoing a surgical procedure are found to have a
greater incidence of perioperative adverse events and hemodynamic instability, unplanned
postoperative ICU admissions, increased length of hospital stay, and substantial long-term
morbidity.3,4 According to the recent autopsy series the incidence of unexpected perioperative
mortality among COVID-19 patients undergoing a surgical procedure has been estimated as
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high as 20 %.5 The evidence suggests the high mortality rates observed among COVID-19
patients are largely due to unrecognized thromboembolic complications, including deep vein
thrombosis (DVT) and pulmonary embolism (PE).4,5 Several case reports corroborate the
high incidence of venous thrombosis and pulmonary embolism in the setting of COVID-19
pneumonia despite prophylactic anticoagulation. While the exact estimate of the incidence of
venous thromboembolism (VTE) in COVID-19 patients remains unclear, the accumulating
evidence reports rates varying between 4.8% and 85%, with pulmonary embolism being the
most common thromboembolic complication.7 VTE is often an unrecognized asymptomatic
event that may be detected early through appropriate monitoring. Early detection can lead to
better outcomes; thus, the importance of close monitoring and screening for DVTs in patients
with COVID-19 is gaining widespread recognition. Additionally, a lack of consensus in the
literature regarding optimal anticoagulation regimen, time of initiation, and duration of the
therapy in this high-risk patient population further contribute to the development of acute
VTE, risking a potentially fatal outcome.9 As the key members of the perioperative arena who
provide the majority of the direct patient care, anesthesia providers, must be knowledgeable
of the risks and associated complications of VTE as well as the available safety measures and
recommendations for the surgical patient population with COVID-19.
Diagnosis of VTE, challenging under usual circumstances, is even more complex
when associated with COVID-19. Traditionally D-dimer cutoff levels are used to decide
whether further imaging, such as Computed Tomography Angiogram (CTA), is warranted. In
COVID-19 patients, D-dimer levels seem to be intrinsically elevated, thereby making it a less
useful tool to risk-stratify COVID-19 patients.7,8 Furthermore, access to the CTA may be
limited due to risk transmission and cross-contamination. Alternatively, the use of point-ofcare ultrasound (POCUS) of the lower extremity has been shown to be a safe, rapid, and
accurate method for the detection of DVT when integrated in the preoperative assessment for
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patients with COVID-19.8, 10-14 Generally, the concept of POCUS refers to the use of portable
ultrasonography at a patient’s bedside for therapeutic, procedural, and diagnostic purposes.
Growing evidence suggests that POCUS contributes to earlier and improved diagnosis, helps
to reduce the cost of care, and improves patient outcomes.9 It represents an attractive option
during the Covid-19 pandemic since it is portable technology helps to reduce exposure and
transmission of infection. The use of POCUS in Covid-19 patients has been endorsed and
encouraged by the American College of Chest Physicians (ACCP) expert panel and the
American College of Emergency Physicians (ACEP). The ACCP suggested using lower
extremity POCUS as part of screening in COVID-19 patients with suspected pulmonary
embolism, unexplained right ventricular dysfunction, or unexplained refractory
hypoxemia.2,3,5 The American Association of Nurse Anesthetists (AANA) recognizes the
importance of POCUS as a critical core skill that CRNAs should possess. Gavazzi et al5 in
their report, strongly suggested a close vein ultrasound screening and monitoring to be
performed in all COVID-19 patients to screen for DVTs.
In patients with COVID-19, the POCUS exam for lower extremity DVT consists of
two-dimensional venous compression and yields results similar to formal vascular studies.10,1
Because proximal lower extremity thrombi have the highest risk of embolization, evaluation
of the common femoral vein, femoral vein, and popliteal vein is most important. Either
inability to compress a vein completely with wall-to-wall apposition or visualization of
echogenic thrombus within the vein is diagnostic of DVT.8.12,15 Acute thrombi are gelatinous
and may appear anechoic, while subacute or chronic thrombi are echogenic, but all veins with
a DVT will not compress complete 10,12,13
Published reports revealed 91% sensitivity and 98 % specificity of the compression
POCUS exam in detecting lower extremity DVT.16,17 Additionally, the literature suggests that
using POCUS in the diagnosis of lower extremity DVT may help avoid unnecessary medical
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interventions and diagnostic tests, therefore representing the potential quality of care and
cost-saving improvements.13-17
Despite the literature demonstrating the positive outcomes of the compression
POCUS exam, published consensus guidelines have not yet included its implementation as a
standard intervention for preventing VTE. Determining the value and clinical utility of
POCUS in a preoperative setting could as the initial step toward establishing objective,
evidence-based clinical implications for reducing the adverse outcomes of theCOVID-19associated coagulopathy. This literature review will present a synthesis of the current
evidence regarding point-of-care ultrasonography’s utility in preventing of VTE in patients
with confirmed COVID-19 undergoing surgical procedures.
Background and Pathophysiology
The pathophysiological mechanisms of the VTE formation can be traced back to
Virchow’s Triad, which proposes that venous thrombosis is the result of at least one of three
etiologic factors: hypercoagulability, endothelial injury, and venous stasis.4,5 Patients
suffering from COVID-19 are at particularly high risk for developing VTE as the emerging
evidence postulates that all three contributing factors of the Virchow’s triad apply in COVID19 10,12,16 (Figure 1). The viral interaction of SARS-CoV-2 with angiotensin-converting
enzyme (ACE-2) receptors has been suggested to cause the injury and consequent
dysfunction of the vascular endothelium.4-6 Research has shown that SARS-CoV-2, the
causative pathogen for COVID-19, enters cells through ACE-2 receptors located in type two
alveolar cells, intestinal epithelium, and vascular endothelium. 3-6 Specifically, the viral
surface spike (S) protein binds to ACE2 on host cells, triggering viral endocytosis.6 The
fusion peptide of the S subunit inserts into the host cell membrane. Once inserted, the S
protein folds upon itself, bringing its two heptad repeat regions together, which fuses the cell
membranes and releases the viral package into the host cell.6,8 Once inside host cells, the
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virus induces cell injury that activates a highly inflammatory process of the host cell death
known as pyroptosis, ultimately causing the widespread damage and dysfunction of the
vascular endothelium.3-6 The inflamed and injured vascular endothelial cells facilitate the
recruitment of leukocytes, macrophages, and mast cells, which have important roles in
immunity.6 An aggressive viral infection induces apoptosis of lymphocytes and consequent
lymphopenia.. The protective immune system leads to the release of molecules such as Creactive protein, fibrinogen, ferritin, D-dimer, and pro-inflammatory cytokines, including
interleukin-6 (IL-6).6 A progressive dysregulated immune response to SARS-CoV-2 viral
infection with the synthesis of IL-6 and other inflammatory mediators, the so-called cytokine
storm, contributes in turn to activate the complement system, clotting cascade, thus causing a
state of hypercoagulability.5,6
Additional anesthesia-related factors contributing to venous stasis and stimulation of
coagulation include prolonged operative/anesthetic exposure time, vasodilatory effects of
anesthesia medications, muscle relaxation, and decreases in core body temperature.7 Finally,
mechanical ventilation, central venous catheterization, and surgery cause additional vascular
endothelial injury, nearly doubling the risk of developing vessel thrombosis.7
Purpose of the Study
The purpose of this study is to improve anesthesia provider knowledge on the use of
POCUS in the prevention of perioperative VTE in patients with COVID-19 undergoing
noncardiac surgical procedures, as well as improve recognition of associated risk factors that
predispose patients to the development of VTE. An educational intervention will be
provided to certified registered nurse anesthetists as part of a quality improvement project.
The goal is to improve provider knowledge and the likelihood of utilizing POCUS to
prevent perioperative VTE in patients with COVID-19 undergoing noncardiac surgical
procedures. An increased participants’ knowledge surrounding the pathophysiological
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mechanisms of VTE formation in COVID-19 patients, the pitfalls of the current VTE
prevention practices and recommendations, and the benefits of perioperative use of POCUS
modality may help in the early identification of VTE and potentially reduce the risk of
perioperative thromboembolic events. The overall objective of the project is to increase the
quality of healthcare delivery and improve healthcare outcomes for surgical patients with
COVID-19 undergoing noncardiac surgery.
THE LITERATURE REVIEW
Purpose of the Literature Review
This literature review will present a synthesis of the current evidence regarding PointOf-Care Ultrasonography’s utility in the preventing VTE in patients with confirmed
COVID-19 undergoing surgical procedures. The literature review includes primary research
studies answering the PICO question: “In the adult patients with COVID-19 (P), does the
use of the POCUS modality as an adjunct to preoperative screening for DVT (I), compared
to its non-use (C), improve the early identification of perioperative VTE (O)? The literature
review is used to provides the educational framework to improve provider knowledge. The
results obtained from the literature review will be used to formulate an educational
intervention to improve anesthesia provider knowledge on the use of the POCUS modality
for screening for DVT. The overall objective of the project is to increase the quality of
healthcare delivery with the intention of improving healthcare outcomes for patients with
COVID-19 undergoing noncardiac surgery
METHODOLOGY
Strategy and Study Selection
The Preferred Reporting Items for Systematic Reviews and Meta-Analyses
(PRISMA) checklist was used to guide the search and format of the literature review.9 Below
is a PRISMA flow diagram in Figure 1 that provides a visual representation of this literature
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review screening process phases. A comprehensive search was conducted on several
electronic databases, including Medline (ProQuest), Excerpta Medica Database (EMBASE),
and Cumulative Index of Nursing and Allied Health Literature (CINAHL) electronic
databases. The following Medical Subject Headings and free-text terms were used alone and
in combination with the appropriate Boolean filters: venous thromboembolism, deep vein
thrombosis, pulmonary embolism, surgery, Severe Acute Respiratory Syndrome Coronavirus2 (SARS-CoV-2), COVID-19, point-of-care ultrasound, perioperative management,
anesthesia considerations. Filters included English text, full-text availability, scholarly peerreviewed journals, academic journals, and studies published after December 31, 2019. After
studies were gathered through the databases, additional publications were discovered by
finding the primary sources in an article’s reference list. For the identification of additional
and potentially relevant data sources, each article that matched the PICO criteria was
examined along with its respective reference lists. Studies referenced in matching articles
were reviewed for relevance and were included if matching the PICO criteria. Gray literature
databases, including www.clinicaltrials.gov, conference abstracts, and poster presentations,
were explored to reduce reporting bias. The titles and abstracts of relevant results were
evaluated using predetermined inclusion criteria. The search yielded 46 articles related to the
previously mentioned criteria. Of the 46 articles, 9 were found to be relevant and
subsequently included in this literature review.
Full text of each relevant article was obtained, and data were extracted for analysis.
Information extracted from each study included population, study design, type of procedure,
intervention, and primary outcome measures. Published guidelines and current
recommendations from the ACCP and the ASPS were also included in this literature review.
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Identification

Figure 1. PRISMA Flow Diagram

Records identified through
database searching (CINHAL,
EMBASE, and MEDLINE)
(n = 73)

Additional records
identified through
other sources
(n = 0)

Screening

Records after duplicates removed
(n = 37)

Records screened
(n = 34)

Eligibility

Full-text articles assessed for
eligibility
(n = 28)

Included

Studies to be included in
qualitative synthesis
(n = 9)
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Records excluded
(n=6)

Full-text articles excluded,
with reasons:
(n = 17)
Does not meet patient
population requirement
(n = 2)
Does not meet intervention
requirements
(n = 2)
Does not meet outcome
requirements
(n = 1)
Does not meet language
requirements
(n = 1)

Data Collection and Analysis
The selected studies were evaluated using John Hopkin’s Nursing Evidence-based
Practice process to determine the strength and quality of research. According to John
Hopkin’s strength of research evidence rating scheme, level I evidence comprising of
evidence obtained from an experimental study, randomized controlled trial, or systematic
review of randomized controlled trials, with or without meta-analysis, is considered the
strongest level of evidence.13 Level II evidence includes evidence obtained from a quasiexperimental study or a systematic review which includes quasi-experimental studies, with or
without meta-analysis.13 Level III evidence obtained from a quantitative non-experimental
study (e.g., observational cohort study), qualitative study, or a systematic review consisting
of either, is considered the lowest level of evidence.13
Research evidence is further evaluated and determined to be of high-quality, good quality, or low-quality evidence. “High” quality evidence contains consistent and
generalizable results, a sufficient sample size, adequate control, definitive conclusions, and
consistent recommendations based on a thorough literature review established from scientific
evidence.1 “Good” quality evidence contains reasonably consistent results, a sufficient
sample, some degree of control, fairly definitive conclusions, and reasonably consistent
recommendations based on a fairly comprehensive literature review.13 “Low” quality
evidence contains little evidence with inconsistent results, an insufficient sample size, and
lacks any definitive conclusions.13
The selected studies were also evaluated for relevant information consistent with the
purposes of the literature review and stated PICO question. The information obtained and
evaluated from each observational cohort study included: (1) the study design and method,
(2) sample size and characteristics, (3) sample setting, (4) measurement tool and abnormal
threshold value, (5) results of the study, (6) associated risk factors for VTE, (7) limitations of
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the study, and (8) study conclusions. A matrix table was created to summarize the
characteristics and findings from each study, and an evidence rating was assigned to each
study based on John Hopkin’s research evidence appraisal tool.
RESULTS
Several studies have assessed the usefulness of POCUS to diagnose VTE in patients
with COVID-19. Lerardi et al.21 report a deep venous thrombosis (DVT) incidence of 1.6%
among 60 COVID-19 patients routinely screened by bedside ultrasound. In a prospective
study of 156 COVID-19 patients with D-dimer levels > 1000 ng/ml, compression ultrasound
screening for asymptomatic DVT showed an incidence of 14.7%.22 Similar findings have
been reported with another systematic screening for the diagnosis of deep vein thrombosis
(DVT) by lower limb vein compression ultrasonography in 84 consecutive patients despite
uniform pharmacological thromboprophylaxis incidence of 11.9%; 2.4% proximal DVT.23
D-dimer is a laboratory indicator that reputedly predicts fatal outcomes from PE. In
some studies, patients with D-dimers levels of $1.0 mg/L had an 18- fold increased mortality
risk,2 and patients who had died of COVID-19 had had higher levels of D-dimer on
admission compared with those who had survived. In our review, 13 of the included studies
had reported significantly higher D-dimer levels in COVID-19 patients with VTE than in
those without VTE. Therefore, a higher D-dimer level could be an indicator of predicting
VTE and a poor prognosis for VTE patients.
In a retrospective cohort study of 71 treated COVID-19 patients on anticoagulant
thromboprophylaxis, who underwent systematic low limb venous duplex ultrasonography at
hospital discharge or earlier if DVT was clinically suspected, 16 patients developed VTE
(22.5%) and 7 PE (10%).24
Cross-sectional study in Wuhan, China, in 48 patients on low molecular weight
heparin (LMWH) thromboprophylaxis detected lower extremity DVTs in 41 patients
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(85.4%), with 36 (75%) isolated distal DVTs and 5 (10.4%) proximal DVT.25 In another
retrospective study from Wuhan, all 88 patients on LMWH thromboprophylaxis underwent
compression ultrasonography. Here, the overall incidence of DVT was 46%, comprising
proximal DVT in 9 % and distal DVT in 46% .26
Kariyanna et al. retrospectively reviewed a single case of a thrombus in transit in a
critically ill patient with COVID-19 pneumonia, where the initial diagnosis was made with
POCUS. 12 The findings of the study demonstrated that POCUS could be used as an
alternative for screening patients with COVID-19 who are at risk of PE. Similarly, several
other reports confirmed that POCUS could be used to rapidly diagnose pulmonary embolism
and guide management and intervention.5,6,8,12
DISCUSSION
Summary of Evidence
Point-of-care ultrasound (POCUS) is the concept of bedside utilization of ultrasound
to expeditiously receive imaging information that guides appropriate diagnoses, medical
interventions, and acute procedures.11-14,15 POCUS examination enables anesthesia providers
to bring portable ultrasound imaging to the patient’s bedside and perform a study in real
time.11-17 Perioperative ultrasound has been widely used in anesthesiology due to its
simplicity, rapidity, practicality, low cost, absence of radiation, and reproducibility. POCUS
modality has become an indispensable tool for anesthesiologists to evaluate cardiopulmonary
status, guide procedures, and manage emergencies.11,14-16
For diagnostic purposes, POCUS is a safe, fast, effective, and relatively inexpensive
tool that helps address a specific clinical question to guide the evaluation and management of
the patient and is often complementary to the physical examination.18,19 Its ability to
diagnose potentially life-threatening conditions in a timely manner is especially beneficial for
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anesthesia providers in resource-poor settings where access to other types of imaging is not
available.13,14
Point of care ultrasound is a diagnostic modality growing in popularity due to its noninvasive nature and quick application. Its utility lies in its non-invasive application, direct
user interface, and portability, especially in handheld devices, allowing for quick assessment
and triage. Gaps exist in the evidence to guide the choice among available anticoagulants,
dosing, optimal timing of initiation, and duration of therapy for VTE prevention. No
prospective randomized controlled trials exist on the preoperative use of POCUS for VTE
prevention in the COVID-19 patient population This delineates the need to gather highquality clinical evidence by designing large-scale studies implementing ultrasound as a realtime diagnostic and navigation tool for management. Further assessment is needed of the
potential positive or negative implications of using a focused methodology, handheld
technology, and its application by practitioners with limited POCUS training. Larger studies
could provide useful and practice-changing information that, importantly, could be translated
into the management of new emerging respiratory infection outbreaks with a high risk of
human-to-human transmission.
Limitations
There are several noteworthy limitations in our study. First, the studies included in
our analysis are observational. This review included observational cohort studies and thus
were not classified as the highest level of evidence. All studies had defined inclusion and
exclusion criteria, but such criteria were not consistent among the studies. Most of the studies
included in this review were prospective in nature which allowed for a more complete study
design; however, four studies were classified as retrospective. There is limited control over
data collection in retrospective studies, and data may be incomplete, inaccurate, or
inconsistently measured between subjects.31
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Given that there are no randomized clinical trials, it is difficult to eliminate confounding
variables when assessing VTE and clinical associations. Furthermore, the included studies are
heterogeneous with respect to reporting patient demographics, clinical characteristics, method
of VTE diagnosis, and strategy for anticoagulation. These studies suggest an increased
incidence of late or delayed VTE risk 6. Further, the studies did not consistently report the
duration of illness, the severity of illness, hospital length of stay, risk factors for VTE, or
presence of other non-VTE indications for anticoagulation.
Future potential areas of research include arterial thrombosis, the impact of
hypercoagulability risk factors, the occurrence of late-term thrombosis post-discharge, and
the presence of long-term coagulopathy. As worldwide cases continue to surge, VTE risk in
non-hospitalized patients with less acute and non-pneumonia COVID-19 infection also
warrants further investigation.
CONCLUSION
Perioperative thromboembolic event, including deep vein thrombosis or pulmonary
embolism, is a complication that can result in substantial patient morbidity and mortality.
Traditionally, D-dimer cutoff levels are used to decide whether further imaging, such as
Computed Tomography Angiogram (CTA) is warranted. In COVID-19 patients, D-dimer
levels seem to be intrinsically elevated, thereby making it a less useful tool to risk-stratify
COVID-19 patients.7,8 Furthermore, access to the CTA may be limited due risk transmission
and cross-contamination. The preoperative incorporation of POCUS modality has been
shown to accurately assess for the presence of DVT. Examination with POCUS provides
anesthesia providers with relevant clinical information and can be performed in real-time at
the bedside. Point-of-care ultrasound screening for DVT may be a resource-sparing
alternative in the setting of the COVID-19 pandemic.

Page 17 of 50

METHODOLOGY OF QUALITY IMPROVEMENT
Setting and Participants
The primary objective of this quality improvement (QI) project is to improve
healthcare provider knowledge on the role of Point-Of-Care Ultrasonography (POCUS) in the
prevention of perioperative Venous Thromboembolism (VTE) in patients with COVID-19
undergoing noncardiac-surgical procedures and to determine the efficacy of a PowerPoint
educational intervention to meet this objective. To successfully achieve the goals of this
quality improvement project, a series of actions will be conducted that involve a specific
group of study participants receiving an educational intervention on the utility of POCUS in
preventing perioperative VTE in patients with COVID-19. The setting of this QI project will
take place across four hospitals located in Broward County, Florida. Broward Health Medical
Center contains 716 beds, Broward Health North contains 409 beds, Broward Health Coral
Springs contains 250 beds, and Broward Health Imperial Point contains 204 beds. The Salah
Foundation Children’s Hospital within Broward Health Medical Center contains 125 beds.
Primary participants include all certified registered nurse anesthetists (CRNAs) employed by
Anesco Broward North Anesthesia Group, LLC (Anesco), which provides anesthesia services
for all four hospitals in the district. The participants will be recruited voluntarily, and the
anticipated sample size will be between 5-15 participants.
Description of Approach and Project Procedures
The primary methodology of the proposed project is to administer an online
educational intervention to anesthesia providers which focus on the benefits of POCUS
utilization in the prevention of perioperative VTE in patients with COVID-19. A virtual pretest/post-test design will be used to evaluate outcomes. The target population will comprise
approximately 10 anesthesia providers working for Broward Health. With their virtual
consent, participants will complete a virtual, anonymous pre-test survey to assess their

Page 18 of 50

knowledge, perceptions, and current clinical practices regarding the use of Point-Of-Care
Ultrasonography (POCUS) in the prevention of perioperative venous thromboembolism
(VTE) in patients with COVID-19 undergoing noncardiac surgical procedures. The virtual
pre-test survey is to be completed individually and is expected to take up to 5 minutes. Then,
the participants will view a virtual 10-minute educational PowerPoint based on the results of
a related systematic review. Participants will be asked to complete a virtual post-test, which
will be identical to the pre-test. A virtual post-test survey is expected to take 5 minutes to
complete. Data will be collected using the pre-test/post-test survey form attached. No
identifiable private information is to be collected. Demographic data, including gender, age,
ethnicity, and title, will be obtained as part of the survey. Additionally, the pre-test/post-test
survey will be used to collect data related to participants’ knowledge, perceptions, and
practices related to using POCUS in the prevention of perioperative VTE in COVID-19
patients. All data analysis will be completed virtually. No face-to-face contact will be
required. The participants will watch the educational module and take the pre and post-test
from the electronic device they use to open the survey. As a result of this project, it is
expected that participants will gain increased knowledge of the uses and benefits surrounding
the utilization of the POCUS modality for the prevention of perioperative VTE. Furthermore,
it is expected that this project will benefit COVID-19-positive patients presenting for a
surgical procedure.
Protection of Human Subjects
As this is an educational intervention, there is no to minimal risk to participants. Risks
are outlined in the consent (see Appendix B). Participation is voluntary, and there is no
penalty if participants decide to withdraw from the QI project. Anonymity will be ensured
under the Qualtrics survey platform, and the investigator will obtain no personal factors that
could identify the subjects. Additionally, Institutional Review Board (IRB) approval will be
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gained before any intervention will be carried out (see Appendix C). The anonymous results
will be secured via the utilization of randomized code identifiers. The electronic data
collected from pre-, and post-test will be maintained on a password-protected laptop.
Data Collection
The primary data collection instruments will include a pre-assessment and postassessment questionnaire to determine the effects of the education intervention. Both
assessments will be conducted using surveys of approximately 10 questions focusing on
knowledge and practice using Qualtrics. The pretest will gauge knowledge and current
perspectives on the educational material, while the post-test survey will determine if the
participants gained knowledge from the intervention and will apply their knowledge to the
practice environment. Demographic data, including gender, age, ethnicity, and title will be obtained
as part of the survey. Additionally, the pre-test/post-test survey will be used to collect data related to
participants’ knowledge, perceptions, and practices related to the use of POCUS in the prevention of
perioperative VTE in COVID-19 patients. The data will be exported from Qualtrics to the

Statistical Package for the Social Sciences (SPSS), and an analysis will be conducted. The
data collected will be confidential and no subject identifiers will be recorded during any
component of the study.
Data Management and Analysis Plan
The co-investigator DNP student will extrapolate statistically significant data from
SPSS, utilizing this to establish patterns of change from participants. Growth or decline in
knowledge from pre-test to post-test will be compared using random identification numbers
(ID) allocated by the Qualtrics platform to preserve anonymity. Each question will be
assessed, and measurements will be taken to establish personal change, change amongst the
group, and the overall effectiveness of the educational intervention. Data collected will
remain on a password-protected computer.
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RESULTS OF QUALITY IMPROVEMENT
Pre-test and Post-test Demographics
The pre-test and post-test demographics are identified in Table 1, shown below.
Table 1. Participant Demographics
Demographics
Total Participants
Gender
Male
Female
Age
<18 yr
18 – 29 yr
30 – 49yr
> 50 yr
Ethnicity
Hispanic
Caucasian
African American
Asian/Pacific-Islander
Other
Education
Masters
Doctorate
Years of CRNA Practice
0 – 2 yr
2 – 5 yr
5 – 10 yr
10 – 20 yr
> 20 yr
Title
CRNA
MD

N (%)
8 (100%)
5 (40%)
7 (60%)
0 (0%)
4 (30%)
8 (70%)
0 (0%)
1 (8%)
9 (75%)
1 (8%)
1 (8%)
0 (%)
2 (16%)
10 (84%)
3 (25%)
7 (58%)
1 (8%)
1 (8%)
0 (0%)
8 (100%)
0 (0%)

Twelve participants initially started the pre-test survey, three of whom failed to
complete the post-test survey. One CRNA neglected to enter their random ID number to
allow the project’s co-investigator to assign pre and post-test scores to the right surveyor.
Subsequently, their data was omitted during dissemination. Eight anesthesia providers
accurately followed the pre-test and post-test instructions, and their demographics are
presented in Table 1. Most participants were female (n=5, 62.5%), instead of male (n=3,
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37.5%). Most individuals were also in the 25 to 35 age group (n=5, 62.5%). The remaining
participant’s ages were as follows: 36 to 45 years old (n=1, 12.5%), 46 to 55 years old (n=2,
25%), and no individuals from the 55 to 66-year age group. Various ethnicities were also
represented amongst the surveyors Hispanic (n=4, 50%), African American (n=1, 12.5%),
Asian (n=1, 12.5%), and other (n=1, 12.5%). There were no participants who identified as
Caucasian. Information was obtained about the participant’s level of education, and it was
found that the majority had a doctorate degree (n=6, 84%), and only a few had a master’s
degree (n=2, 16%). All participants in this quality improvement project were CRNAs (n=8,
100%). Finally, individuals were asked about their years of CRNA practice: 0 - 2 years (n=4,
50%), 2 - 5 years (n=1, 12.5%), 5 - 10 years (n = 1, 12.5%), 10 - 20 years (n=2, 25%).
Table 4. Difference in Pre-Test and Post-Test Knowledge
Correct Responses

Pre-Test

Depending on patient risk factors, the
incidence of VTE in covid-19 can be as high
as: 80%
Which of the following statements best
defines venous thromboembolism? A blood
clot that manifests as a spectrum of
sequelae, including deep vein thrombosis
(DVT) and/or when it dislodges and
migrates, a pulmonary embolism (PE).
Which of the following is NOT associated
with VTE? Reduced costs of care and
earlier discharge
Which of the following is NOT considered a
significant risk factor for VTE? Female
gender
What is the most common anatomic site of
venous thrombosis formation? Lower
extremities
The use of point-of-care ultrasound
(POCUS) of the lower extremity has been
shown to be a safe, rapid, and accurate
method for detecting DVT when integrated
into the preoperative assessment for patients
with COVID-19: True

Post-Test

Difference

62.5%

50%

12.5%

50%

37.5%

100%

87.5%

-12.5%

100%

87.5%

-12.5%

75%

87.5%

12.5%

62.5%

62.5%

0%

12.5%
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What makes POCUS an attractive option in
preventing perioperative VTE complications
in COVID-19? All of the above
Which of the following is TRUE? All of the
above

100%

100%

0%

100%

87.5%

-12.5%

Pre-test and Post-test Knowledge and Perspective of Use in Practice
If the modality was offered at their facility, the participants were asked how likely
they would utilize the POCUS modality to screen for DVT in COVID-19 patients undergoing
noncardiac surgery. A positive correlation was found between the pre and post-test data. Preeducation, 37.5% of CRNAs said they were extremely likely to use it, while 62.5% of
CRNAs were extremely likely to use it post-education. The same amount of CRNAs (n = 3 or
37.5%) was somewhat likely to use before and after the educational intervention. 25% of
participants were neither likely nor unlikely to use the POCUS modality to screen for DVT in
the pre-test but changed their perspective to extremely likely in the post-test. Table 2 depicts
the likelihood of CRNAs using the POCUS modality to screen for DVT in COVID-19 patients
at their facility.
Table 2. Differences in Pre-Test and Post-Test Perspective
If available at your facility, how likely are you to
utilize the POCUS modality to screen for DVT in
COVID-19 patients undergoing noncardiac
surgery?
Extremely likely

PRETEST

POSTTEST

DIFFERENCE

37.5%

62.5%

25%

Somewhat likely

37.5%

37.5%

0%

Neither likely nor unlikely

25%

0%

-25%

Somewhat unlikely

0%

0%

0%

Extremely unlikely

0%

0%

0%
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If the modality was offered at their facility, the participants were asked how likely
they were to recommend the use of the POCUS modality to screen for DVT in COVID-19
patients undergoing noncardiac surgery. A positive correlation was found between the pre
and post-test data following the educational intervention. Two participants (25%) were
somewhat likely to recommend the utilization of POCUS modality to screen for DVT in
COVID-19 patients, as opposed to no participants prior to the intervention. However, 62.5%
of participants exhibited no change in perspective, and one participant (12.5%) exhibited a
negative change in perspective. Overall, 50% of participants were either somewhat unlikely
(n=3, 37.5%) or extremely unlikely (n=1, 12.5%) to recommend the POCUS modality, an
improvement from 62.5% before educational intervention. Two participants (25%) remained
indifferent and were neither likely nor unlikely to recommend POCUS modality to screen for
DVT in COVID-19 patients undergoing surgery. Table 3 depicts the likelihood of the
participants recommending the use of POCUS modality to screen for DVT in COVID-19
patients if available at their facility.
Table 3. Differences in Pre-Test and Post-Test Perspective
How likely are you to recommend
POCUS modality to screen for DVT in
COVID-19 patients undergoing
noncardiac surgery?
Extremely likely

PRE-TEST

POSTTEST

DIFFERENCE

0%

0%

0%

Somewhat likely

0%

25%

25%

Neither likely nor unlikely

37.5%

25%

-12.5%

Somewhat unlikely

50%

37.5%

-12.5%

Extremely unlikely

12.5%

12.5%

0%

Summary of Data
The results demonstrate an overall gain in knowledge between pre- and post-testing,
with only one participant with a lower post-test than from pre-test score. A bar graph
comparing results is depicted below in Table 4. In general, pre-test assessments show an
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average score of 54% compared to 68% on post-test assessments. The overall average
improvement between pre-and post-test assessments was 14%. Only 5 out of the 8
participants (62.5%) who completed the study showed an improvement in knowledge
following the intervention, with an average increase of 24.4% between pre- and postassessment scores. The remaining participants either had no change in knowledge (n=2, 22%)
or had a decrease in knowledge (n=1, 11%) despite the education provided.
Table 4. Pre and Post-Test Scores
100%

80%

60%

89% 1
67%
56%

67%

67% 2

78% 6
56%

67% 3
56%
56% 4

33% 34%. 8

44% 5
22%. 6

22%. 7

11%. 3

20%
0%. 2
0%

67% 8

44%

33%. 1

40%

78% 7
56%

1

2

0%. 5
3

4

5

6

7

8

-11%. 4

-20%
Pre-test

Post-test

Improvement

Out of the participants who showed improvement in knowledge between pre- and
post-test assessments (n=5), one participant (20%) was more likely to utilize following the
intervention. Two participants (40%) remained somewhat unlikely to employ the POCUS
modality, one participant (20%) remained neither likely nor unlikely to employ, the POCUS
modality and one participant (20%) was less likely to employ the POCUS modality after the
intervention, despite improvement in knowledge.
DISCUSSION
Limitations
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One limitation of this project is the small sample size. Many subjects that were eligible to
participate in the study chose not to. Twenty-eight members of the Broward Health anesthesia
department distributed the survey via e-mail, and only twelve people participated in the
project. A small sample size can impact the reliability and validity of a study. In the future,
the survey could be distributed to more subjects across different hospital systems to increase
the sample size. Also, the survey link, which contained both surveys and the PowerPoint
presentation, was only available online for two weeks, perhaps increasing the time allotted to
review the material and surveys could have increased the number of responses. Lastly, the
project was implemented completely online, hindering its delivery by other methods. A more
controlled, in-person setting could have yielded more accurate results. As this project was
volunteer based, there is an inherent risk of self-selection bias. Finally, sample attrition
occurred, which could have potentially impacted the final results of the study. Though the
investigators strived for concise instructions on the survey link, three participants who
completed the pre-test failed to finish the post-test. Further, one individual who finished their
pre-and post-testing neglected to enter their random ID number to allow the project’s coinvestigator to assign pre and post-test scores to the right surveyor.
Future Implications for Advanced Nursing Practice
Early identification of VTE through POCUS surveillance allows appropriate
interventions to occur, reducing morbidity and mortality in the COVID-19 patient population
undergoing noncardiac surgery. Despite the literature demonstrating the positive outcomes of
the clinical utility of POCUS in the early identification of thromboembolic events, published
guidelines have not yet included its implementation as a standard intervention in the
prevention of VTE.5,6,9-12 The outcomes of this study are important in determining strategies
available to participants that will increase knowledge and potentially change practice to
improve patient outcomes in COVID-19 patients undergoing noncardiac surgery. According
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to the data collected, the educational intervention provided was effective in improving the
knowledge of anesthesia providers on the role of POCUS in the prevention of perioperative
VTE in patients with COVID-19. Participants have demonstrated stronger attitudes and
beliefs regarding the high incidence of VTE in COVID-19-positive patients and the
significance of its early identification. Furthermore, there was an increase in the likelihood of
using POCUS screening in this high-risk surgical patient population. The results of this study
can be applied to a wider audience of Certified Registered Nurse Anesthetists. As research
continues to be conducted on the management strategies for COVID-19, increasing
awareness of the high incidence of VTE as well as the role of POCUS in their prevention, can
reduce mortality and improve overall patient outcomes.
Conclusion
Diagnosis of VTE, challenging under usual circumstances, is even more complex
when occurring in association with COVID-19.2,3,8 Traditionally D-dimer cutoff levels are
used to decide whether further imaging, such as Computed Tomography Angiogram (CTA),
is warranted. In COVID-19 patients, D-dimer levels seem to be intrinsically elevated, thereby
making it a less useful tool to risk-stratify COVID-19 patients.3,4 The unrecognized
thromboembolic event, including deep vein thrombosis or pulmonary embolism, is a
complication that can result in substantial patient morbidity and mortality. It has serious
consequences as unrecognized PE is associated with increased morbidity and mortality within
30 days of surgery, resulting in significant utilization of healthcare resources.4-6 As the new
variants of COVID-19 continue to emerge, it becomes essential for anesthesia providers to be
informed of the unique anesthetic considerations for this population, including the
management and prevention of VTE. Furthermore, anesthesia providers must be
knowledgeable of the preventable measures that can reduce the incidence of perioperative
PE. Implementing an educational module on POCUS for reducing perioperative VTE can
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enhance anesthesia provider knowledge, strengthen the beliefs and attitudes of anesthesia
providers, and increase the likelihood of using this modality in the COVID-19 population to
improve the quality of care and patient outcomes.
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Appendix A: Overview of Literature Review Results
Evidence
Source

Design/
Method

Lerardi et al.
(2020) 21

Retrospective
single center
observational
cohort study.

DemeloRodríguez et
al. (2020) 22

Prospective
single center
observational
cohort study.

Subject
Selection/
Sample
Size and setting
234 patients with
COVID-19, diagnosed
according to the World
Health Organization
guidelines, hospitalized
between March 15th and
April 7th, 2020, with the
mean age of 61.63 years,
including 164 females
(70%) and 70 males
(30%), screened for
asymptomatic DVT.

156 patients, ≥ 18 years
old (65.4% male), mean
age of the sample 68,
hospitalized in the first
half of April 2020, in nonintensive care units with
diagnosis of COVID-19
pneumonia, screened for
asymptomatic DVT.
COVID-19 diagnosis
defined by positive PCR
or by the presence of
radiological and analytical
findings.

Measurement
Tool/ Scanning
technique

Results

Conclusions

3‐point compression
US examinations of
bilateral legs (common
femoral vein,
saphenofemoral
junction, and popliteal
vein). Ultrasound
examinations were
performed using
portable US machines
with the linear probe.
The lack of
vein compression was
the diagnostic criterion
for the diagnosis of
DVT.
4-point compression
ultrasound examination
of bilateral legs,
including proximal
(common femoral vein,
saphenofemoral
junction, femoral vein,
popliteal vein) and
distal area (calf veins).
Ultrasound
examinations
performed using
portable US machines
with the linear probe.
The lack of

Overall incidence of DVT was 10.7%
(25/234): 1.6% (1/60) among moderate
cases, 13.8% (24/174) in severely and
critically ill patients. Prolonged bedrest
and intensive care unit admission were
significantly associated with the
presence of DVT (19.7%). Fraction of
inspired oxygen, P/F ratio, respiratory
rate, heparin administration, D-dimer,
IL-6, ferritin, and CRP showed
correlation with DVT.

DUS may be considered a useful
and valid tool for early
identification of DVT. High rate
of DVT found in severe patients
and its correlation with respiratory
parameters and some significant
laboratory findings suggests that
these can be used as a screening
tool for patients who should be
getting DUS.

CUS was positive for DVT in 23
patients (14.7%), of whom only one was
proximal DVT. Seven patients (4.5%)
had bilateral distal DVT. Patients with
DVT had higher median D-dimer levels:
4527 ng/ml vs 2050 ng/ml; D-dimer
levels > 1570 ng/ml were associated with
asymptomatic DVT.

In patients admitted with COVID19 pneumonia and elevated Ddimer levels, the incidence of
asymptomatic DVT is similar to
that described in other series.
Higher cut-off levels for D-dimer
might be necessary for the
diagnosis of DVT in COVID-19
patients.
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Pieralli et. al.
(2020) 23

Prospective
multicenter
observational
cohort study.

Artifoni et al.
(2020) 24

Retrospective
multicenter
observational
cohort

227 consecutive patients
admitted between March
21st
and May 25th, 2020, ≥
18 years old, with a
definitive diagnosis
of SARS-CoV-2
pneumonia. The diagnosis
of SARS-CoV-2 infection was
made by PCR.

vein compression was
the diagnostic criterion
for the diagnosis of
DVT.
A 3-point US
compression
examination of bilateral
legs (the common and
superficial femoral
veins, and the popliteal
veins). The lack of
vein compression was
the diagnostic criterion
for the diagnosis of
DVT.

71 consecutive patients
with confirmed COVID19 admitted for more than
48 hours in non-intensive
care units between March
25, 2020, and April 10,
2020, screened by US for
DVT. COVID-19
diagnosis defined by
positive PCR or typical
pattern on chest CT-scan.

A 4-point US
compression
examination of bilateral
legs for DVT at
hospital discharge or
earlier if thrombosis
was clinically
suspected. Chest angioCT scan was performed
in case of suspicion of
pulmonary embolism.

The incidence of DVT was 13.7% (6.2%
proximal, 7.5% distal), mostly
asymptomatic. All patients received
anticoagulation (enoxaparin 95.6%) at
the following doses: low 57.3%,
intermediate 22.9%, high 19.8%.
Patients with and without DVT had
similar characteristics, and no difference
in anticoagulant regimen was observed.
DVT patients were older (mean 77±9.6
vs 71±13.1 years) and had higher peak
D-dimer levels (5403 vs 1723 ng/mL).
Peak D-dimer level >2000 ng/mL was
the most accurate cut-off value able to
predict DVT.

The incidence of DVT in acutely
ill patients with COVID-19
pneumonia is relevant. A
surveillance protocol by serial
CUS of the lower limbs is useful
to timely identify DVT that would
go otherwise largely undetected.

Out of 71 patients, 16 developed VTE
(22.5%) and 7 PE (10%) despite
adequate thromboprophylaxis. D-dimers
at baseline were significantly higher in
patients with DVT. Demographics,
comorbidities, disease manifestations,
severity score, and other biological
parameters, including inflammatory
markers, were similar in patients with
and without VTE. The negative
predictive value of a baseline D-dimer
level < 1.0 µg/ml was 90% for VTE and
98% for PE.

The positive predictive value for
VTE was 44% and 67% for Ddimer level ≥ 1.0 µg/ml
and ≥ 3 µg/ml, respectively. The
association between D-dimer level
and VTE risk increased by taking
into account the latest available Ddimer level prior to US
examination for the patients with
monitoring of D-dimer.
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FrancoMoreno
et al.
(2021) 25

Prospective
observational
cohort study

26 consecutive patients
≥ 18 years old, with
mean median age of 60
years old, admitted in
the internal medicine
ward with a diagnosis of
COVID-19 between
March 30, 2020, to May
6, 2020,
screened for DVT in the
lower extremities with
compression ultrasound.

A 3-point US compression
examination of both legs,
which included the
proximal area (common
femoral vein,
saphenofemoral junction,
and popliteal vein).
The ultrasound
examination was
considered pathological if
compression did not cause
complete collapse of the
examined vein.

Compression ultrasound findings
were positive for DVT in 2 patients
(7.7%; 95% confidence interval,
3.6%-11.7%). Patients with DVT
had central and bilateral PE. In
both, venous thromboembolism
was diagnosed in the emergency
department, so they did not receive
previous prophylactic therapy with
low-molecular-weight heparin.
Patients without DVT had higher
median d-dimer levels: 25,688
μg/dL versus 5310 μg/dL.

Study showed a low incidence of
DVT in a cohort of patients with
COVID-19 and PE. This
observation suggests that PE in
these patients could be produced
mainly by a local
thromboinflammatory syndrome
induced by severe acute respiratory
syndrome coronavirus 2 infection
and not by a thromboembolic
event.

GarciaCeberino
et al.
(2021) 26

Retrospective
single center
observational
cohort study

87 patients older than 18
years with a confirmed
diagnosis of COVID-19
admitted to a hospital in
Granada, Spain, between
April 22nd and 30th
2020. Diagnosis of
COVID-19 pneumonia
was defined as a positive
PCR test along with
radiological findings
consistent with
pneumonia.

Lower extremity
ultrasound (US) performed
at the bedside using a 2point technique consisting
of assessing
compressibility of
common femoral vein
(CFV) and popliteal vein
(PV). Lack of vein
compression was the
diagnostic criterion for the
diagnosis of DVT.

DVT was found in 4 patients (3
femoral, 1 popliteal), of which 1
had not received low molecular
weight heparin (LMWH)
prophylaxis. 21 CT pulmonary
angiograms were performed, being
positive for PE in 5 cases (23.8%);
only 2 of these patients suffered
DVT.

POCUS is a helpful tool detecting
DVT in COVID-19 patients. Study
found a DVT prevalence of 4.6%.
However, the absence of DTV did
not exclude the presence of PE.
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Appendix B: Recruitment Letter

Nicole Wertheim College of Nursing and Health Sciences
Department of Nurse Anesthetist Practice

Educational Module on the Clinical Utility of Point-Of-Care Ultrasonography (POCUS) in
the Early Identification of the Perioperative Thromboembolic Complications in COVID-19
Patients Undergoing Noncardiac Surgery

Dear Broward Health Nurse Anesthetist,
My name is Olga Gay, and I am a student from the Anesthesiology Nursing Program Department
of Nurse Anesthetist Practice at Florida International University. I am writing to invite you to
participate in my quality improvement project. The goal of this project is to improve health care
provider knowledge on the uses of Point-Of-Care Ultrasonography in the early identification of
the perioperative thromboembolic complications in covid-19 patients undergoing noncardiac
surgery. You are eligible to take part in this project because you are a member of the ANESCO
Nurse Anesthetist group currently employed by Broward Health Medical Center.
If you decide to participate in this project, you will be asked to complete and sign a consent form
for participation. Next, you will complete a pre-test questionnaire, which is expected to take
approximately 5 minutes. You will then be asked to view an approximately 15-minute-long
educational presentation online. After watching the video, you will be asked to complete the
post-test questionnaire, which is expected to take approximately 5 minutes. No compensation
will be provided.
Remember, this is completely voluntary. You can choose to be in the study or not. If you'd like to
participate or have any questions about the study, please email or contact me at
ogay001@fiu.edu or 6317456642
Thank you very much.
Sincerely,
Olga Gay, SRNA, FIU
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Appendix C: IRB Exemption Letter
Office of Research Integrity
Research Compliance, MARC 414

MEMORANDUM
To:

Dr. Jorge Valdes

CC:

Olga Gay

From:

Elizabeth Juhasz, Ph.D., IRB Coordinator

Date:

April 8, 2022

Protocol Title:

"An Educational Module on the Clinical Utility of Point-Of-Care
Ultrasound (POCUS) in the Timely Detection of Perioperative
Thromboembolic Complications in COVID-19 Patients Undergoing
Noncardiac Surgery: A Quality Improvement Project"

The Florida International University Office of Research Integrity has reviewed your research
study for the use of human subjects and deemed it Exempt via the Exempt Review process.
IRB Protocol Exemption #:
TOPAZ Reference #:

IRB-22-0143
111504

IRB Exemption Date:

03/22/22

As a requirement of IRB Exemption you are required to:
1) Submit an IRB Exempt Amendment Form for all proposed additions or changes in the
procedures involving human subjects. All additions and changes must be reviewed and
approved prior to implementation.
2) Promptly submit an IRB Exempt Event Report Form for every serious or unusual or
unanticipated adverse event, problems with the rights or welfare of the human subjects,
and/or deviations from the approved protocol.
3) Submit an IRB Exempt Project Completion Report Form when the study is finished or
discontinued.
Special Conditions:

N/A

For further information, you may visit the IRB website at http://research.fiu.edu/irb.

EJ
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Appendix D: QI Project Consent

Nicole Wertheim College of Nursing and Health Sciences
Department of Nurse Anesthetist Practice
CONSENT TO PARTICIPATE IN A QUALITY IMPROVEMENT PROJECT
“An Educational Intervention on the Clinical Utility of Point-Of-Care Ultrasonography
(POCUS) in the Early Identification of Perioperative Thromboembolic Complications in
COVID-19 Patients Undergoing Noncardiac Surgery”

SUMMARY INFORMATION
Things you should know about this study:
Purpose: Educational module concerning the utilization of POCUS in the prevention of
perioperative VTE in patients with COVID-19 undergoing noncardiac surgical
procedures.
Procedures: If you choose to participate, you will be asked to complete a pretest, watch a
voice PowerPoint, and then complete a posttest.
Duration: This will take about a total of 20 minutes.
Risks: The main risk or discomfort from this research is minimal.
Benefits: The main benefit to you from this research is an increase in knowledge on the
perioperative use of POCUS modality.
Alternatives: There are no known alternatives available to you other than not taking part
in this study.
Participation: Taking part in this research project is voluntary.
Please carefully read the entire document before agreeing to participate.
PURPOSE OF THE PROJECT
You are being asked to participate in a quality improvement project. The goal of this project
is to improve anesthesia provider knowledge on the use of POCUS in the prevention of
perioperative VTE in patients with COVID-19 undergoing noncardiac surgical procedures,
as well as improve recognition of associated risk factors that predispose patients to the
development of VTE. The overall objective of the program is to increase the quality of
healthcare delivery and improve healthcare outcomes for surgical patients with COVID-19
undergoing noncardiac surgery.
DURATION OF THE PROJECT
Your participation will require approximately 20 minutes of your time. You will be asked to
complete a pre-test questionnaire, which is expected to take approximately 5 minutes. You
will then be asked to view a short 10-minute educational presentation online. After watching
the video, you will be asked to complete the post-test questionnaire, which should take
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approximately 5 minutes.
PROCEDURES
If you agree to be in the study, we will ask you to do the following:
1. Complete an online pre-test survey via Qualtrics.
2. Review the educational PowerPoint Module lasting 10 minutes.
3. Complete an online post-test survey via Qualtrics.
RISKS AND/OR DISCOMFORTS
Minimal risk, risk not greater than if participant was conducting similar activity. Physical,
psychological, social, legal, and economic risks minimal and no greater than if a participant
was participating in a similar activity. Similar activity such as filling out an online survey
and watching voice over PowerPoint.
BENEFITS
The main benefit from this research is an increase in participants knowledge surrounding the
pathophysiological mechanisms of the VTE formation in COVID-19 patients, the pitfalls of
the current VTE prevention practices and recommendations, and how perioperative use of
POCUS modality can prevent the occurrence of VTE in COVID-19 patients.
ALTERNATIVES
There are no known alternatives available to you other than not taking part in this project.
However, if you would like to receive the educational material given to the participants in
this project, it will be provided to you at no cost.
CONFIDENTIALITY
The records of this project will be kept private and will be protected to the fullest extent
provided by law. If, in any sort of report, we might publish, we will not include any
information that will make it possible to identify you as a participant. Records will be stored
securely, and only the project team will have access to the records.
PARTICIPATION
Taking part in this research project is voluntary.
COMPENSATION & COSTS
There is no cost or payment to you for receiving the health education and/or for participating
in this project.
RIGHT TO DECLINE OR WITHDRAW
You are free to participate in the project or withdraw your consent at any time during the
project. Your withdrawal or lack of participation will not affect any benefits to which you are
otherwise entitled. The investigator reserves the right to remove you without your consent at
such time that they feel it is in the best interest.
RESEARCHER CONTACT INFORMATION
If you have any questions about the purpose, procedures, or any other issues relating to this
research project, you may contact Olga Gay at 631-745-6642/ ogay001@fiu.edu or Dr.
Jorge Valdes at 305-348-7729/jvalde@fiu.edu.
IRB CONTACT INFORMATION
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If you would like to talk with someone about your rights pertaining to being a subject in this
project or about ethical issues with this project, you may contact the FIU Office of Research
Integrity by phone at 305-348-2494 or by email at ori@fiu.edu.
PARTICIPANT AGREEMENT
By clicking the button below, you acknowledge that your participation in the study is
voluntary, you are 18 years of age, and that you are aware that you may choose to terminate
your participation in the study at any time and for any reason.
Please note that this survey will be best displayed on a laptop or desktop computer. Some
features may be less compatible for use on a mobile device.

(Insert Consent to Participate Button Here on the Website)

Appendix E: QI Project Survey
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QI PROJECT SURVEY
Clinical utility of Point-Of-Care Ultrasound (POCUS) in the early detection of
perioperative thromboembolic complications in COVID-19 patients undergoing
noncardiac surgery: A Quality Improvement Project
INTRODUCTION
The primary aim of this QI project is to improve the knowledge of anesthesia providers
on the role of POCUS in the prevention of perioperative VTE in patients with COVID-19
undergoing noncardiac surgical procedures.
Please answer the question below to the best of your ability. The questions are either in
multiple-choice or true/false format and are meant to measure knowledge and perceptions on
the identification and management of perioperative VTE using the POCUS modality.
PERSONAL INFORMATION
1. Gender: Male

Female

2. Age in years: 25 to 30
3. Ethnicity: Hispanic

Prefer not to answer________

31 to 40

41 to 50

Caucasian

51 to 60

African American

61 & older
Asian

Other_________
4. Position/Title: _________________
5. Level of Education: Associates

Bachelors

Masters

Doctoral (DNP, DNAP,

EdD, PhD) Other __________
6. Years of experience:

Less than 1 year

1 to 5
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6 to 10

more than 10 years

CLINICAL UTILITY OF POCUS IN COVID-19 PATIENTS
QUESTIONNAIRE
1. Depending on patient risk factors, the incidence of VTE in COVID-19 can be as high
as:
A. 5%
B. 12%
C. 20%
D. 80%
2. Which of the following statements best defines venous thromboembolism?
E. An autoimmune disorder that primarily targets the respiratory and cardiovascular
systems.
F. An adverse event that generally occurs due to a prolonged imbalance between
myocardial oxygen supply and demand.
G. A blood clot that manifests as a spectrum of sequelae, including deep vein
thrombosis (DVT) and/or when it dislodges and migrates, a pulmonary embolism
(PE).
H. A common perioperative complication requires the presence of an ischemic
feature such as chest pain or EKG changes
3. Which of the following is NOT associated with VTE?
a. Increased 30-day mortality
b. Greater incidence of perioperative adverse events and hemodynamic instability
c. Increased unplanned postoperative ICU admissions and prolonged hospital stay,
substantial long-term morbidity
d. Reduced costs of care and earlier discharge
4. Which of the following is NOT considered a significant risk factor for VTE?
A. Surgery
B. Immobility
C. Advanced stages of cancer
D. Inherited thrombophilia
E. Female gender
5. What is the most common anatomic site of venous thrombosis formation?
A. Lower extremities
B. Coronary Arteries
C. Forearm
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CLINICAL UTILITY OF POCUS IN COVID-19 PATIENTS
D. Coronary Arteries
E. Temple
6. The use of point-of-care ultrasound (POCUS) of the lower extremity has been shown
to be a safe, rapid, and accurate method for detecting DVT when integrated into the
preoperative assessment for patients with COVID-19.
True or False
7. What makes POCUS an attractive option in preventing perioperative VTE
complications in COVID-19?
A. its portable technology helps to reduce exposure and transmission of infection
B. helps to avoid unnecessary medical interventions and diagnostic tests
C. contributes to earlier and improved diagnosis, helps to reduce the cost of care,
and improves patient outcomes
D. All of the above
8. Which of the following is TRUE?
A. In patients with COVID-19, POCUS exam for lower extremity DVT consists of twodimensional venous compression alone and yields results similar to formal vascular
studies.
B. Because proximal lower extremity thrombi have the highest risk of embolization,
evaluation of the common femoral vein, femoral vein, and popliteal vein is most
important.
C. Either inability to compress a vein completely with wall-to-wall apposition or
visualization of echogenic thrombus within the vein is diagnostic of DVT.
D. Acute thrombi are gelatinous and may appear anechoic, while subacute or chronic
thrombi are echogenic, but all veins with a DVT will not compress completely
E. All of the above
9. If available at your facility, how likely are you to utilize POCUS modality to screen for
DVT in COVID-19 patients undergoing noncardiac surgery?
A. Extremely likely
B. Somewhat likely
C. Neither unlikely nor likely
D. Somewhat unlikely
E. Very unlikely
10. How likely are you to recommend POCUS modality to screen for DVT in COVID-19
patients undergoing noncardiac surgery?
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A. Most likely
B. Somewhat likely
C. Somewhat unlikely
D. Most unlikely
E. Very unlikely
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Appendix F: QI Educational Module
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